Harvard Apparatus’ Post

#IATDMCT2024 is almost here! Have you registered yet? 💡 Our program begins with a pre-congress symposium focused on New Frontiers in Clinical Toxicology. In today’s environment, the toxic drug supply constitutes a public health crisis. We will be exploring topics that bring that crisis to light such as wastewater testing (mirroring that which was in place for Covid19 testing); the use of artificial intelligence to help predict and test for novel psychoactive substances that may contribute to the toxic drug supply; we will discover what we can learn from a drug checking service and how that can inform clinical toxicology testing; and we will explore the proliferation of the semi-synthetic cannabinoids.  🎤 Our plenary speakers will offer insights into their respective fields as we explore precision medicine in cancer treatment, the use of psychedelics in psychiatry and health issues of first nations peoples. The Scientific Committee chairs have been working on your behalf to put together symposia that will dive into cutting-edge topics, offering a comprehensive look at the latest advancements in the field. Engage with your colleagues at one or two breakfast roundtables and discuss a topic of mutual interest. 🌐Learn more about our program online here:

🔬 Maximizing Research Impact: Harnessing the Power of Primary Human Cells! 🔬 In the world of research, precision matters. 🌐 When it comes to unlocking the full potential of our compounds, the choice of cellular models is pivotal. 🧪 🔍 Why Primary Human Cells? 1️⃣ Physiological Relevance: Primary human cells closely mimic in vivo conditions, offering a more authentic representation of cellular responses. 2️⃣ Accurate Predictions: Achieve greater predictability in drug responses, ensuring that findings translate effectively from the lab to real-world applications. 3️⃣ Biomimicry Advantage: Leverage the intricate cellular microenvironment for a deeper understanding of compound interactions, optimizing research outcomes. 4️⃣ Reduced Variability: Minimize experimental variables with cells directly sourced from human tissues, enhancing the reproducibility and reliability of your studies. 💡 Elevate Your Research! By incorporating primary human cells, we're not just advancing science; we're pioneering a new era of precision and relevance in our investigations. Let's push the boundaries of discovery together! 🚀 #ResearchInnovation #PrecisionMedicine #ScientificAdvancements #PrimaryHumanCells #DrugDiscovery #ThyrocyteResearch #RelevantInVitro 🔗 Connect with us to explore how primary human cells can amplify the impact of your research! 🤝 #Networking #ScienceCollaboration #ConnectWithUs

Introducing Patholytix Foresight: A suite of ready-to-use AI classifiers designed to identify common rat non-neoplastic lesions. Developed with Charles River Laboratories, our tool offers AI-guided decision support for Pathologists reading Discovery, Lead Optimization, and General Toxicology studies. Official announcement coming soon! 👀 #ToxPath #DigitalPathology #Pathology #DrugDevelopment

Intertek helps catalyze the growth of the pharma and biopharma industry with its expertise in testing, analysis, and areas like R&D. For instance, did you know that we have supported global innovators of oligonucleotide drugs since they first emerged over 25 years ago?  You'll be amazed where you find Intertek! Send us a query at https://lnkd.in/gKp2FMVz to find out more. #ProudtoBeIntertek #BioPharmaceuticals #Pharmaceuticals #Therapeutics

For many labs, it can be a challenge to transition to primary human cells. Join us on Jan. 11 to learn more about why you should consider it anyway. "There are many instances where the extra effort is worth it in terms of improving the translational value," said Sharon Presnell, PhD, LifeNet Health LifeSciences Vice President of Product Development. "During the webinar, I will be covering a case study with human primary thyrocytes that highlights these benefits, through the lens of a toxicology lab." Sign up for Cell Selection for In Vitro Applications: Maximizing Translational Success. https://lnkd.in/dT7akRU

Society of Toxicology (SOT) 2024 is here. Do the limitations of HepG2 or primary human hepatocyte cells have you down? What if you had a liver cell line that didn’t carry the genetic baggage of HepG2, but, had morphology, maturity marker expression, and CYP3A4 function similar to primary human hepatocytes?  You can stop by booth 1812 at your leisure, or, if you prefer to make an appointment, you can book one here: https://lnkd.in/eZM3Kkr5

📢Preventing, Predicting, and Mitigating ADC Toxicities! The 2nd ADC Toxicity Summit returns as the only conference bringing together 80+ experts in toxicology, pathology, translational sciences and more, to exclusively address challenges in minimizing ADC toxicity - https://ter.li/xa0lrc As toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates, join your peers to unlock first-hand insights into how to improve prediction and translation of ADC toxicities to drive more tolerable ADCs successfully into and through clinical development. Discover how to tackle ADC toxicities using in vivo models, enhancing the therapeutic index of ADCs, improving predictability, and much more – find out more here: https://ter.li/xa0lrc Don’t miss out on this unparalleled opportunity to collaborate with industry leaders to navigate the prevention, prediction, and mitigation of ADC toxicities, and make meaningful strides forward in developing safer ADCs. Register before midnight Friday, May 17 to save $850 – https://ter.li/lce30w

🔔 Half-day #workshop on the important topic of #phospholipids at Controlled Release Society (CRS) Annual Meeting in Bologna/Italy. 🗓 July 08, 2024, at 8 am to 12 pm. 📌 Our speakers: Session 1️⃣ on Phospholipids as #excipients Simon Drescher (Phospholipid Research Center Heidelberg): The Phospholipid Research Center Heidelberg: An introduction and ongoing research projects Peter van Hoogevest (Phospholipid Research Center Heidelberg): An Introduction on the use and properties of phospholipid excipients Paulina Skupin-Mrugalska (Poznan University of Medical Sciences): Phospholipids as excipients in (amorphous) solid dispersions Paola Luciani (Universität Bern): Phospholipids in parenteral depot formulations: recent advances, current challenges, and future opportunities Session 2️⃣ on #liposomes and lipid nanoparticles (#LNPs) Mans Broekgaarden, PhD (Université Grenoble Alpes): Radiocontrolled drug delivery with high-Z element-functionalized liposomes Davide Brambilla (Université de Montréal): Phospholipid nanoparticles for lipase deficiency gene replacement therapy Maria Manuela Gaspar (Universidade de Lisboa): Advancing the treatment of infectious diseases – the key role of liposomes as delivery systems Félix Sauvage (Universiteit Gent): Photo-induced destruction of vitreous opacities using nanobubbles generating liposomes Hope to see you! #education #pharma #drugdelivery #genetherapy

🚨 Mohoric et al. published an interesting article introducing two Defined Approach (DA) models based on the existing Bayesian network (BN) modelling approach for skin sensitisation potency assessment. These models aim to increase accessibility and flexibility in skin sensitisation assessment by integrating new approach methodologies (NAMs) with in vitro, in chemico, and in silico methods using publicly available software. This is particularly significant as it promotes a more transparent and reproducible framework, moving towards more animal-free testing. The key elements of the BN-based DAs include: 👉 Incorporation of new in vitro assay data, such as kDPRA, which allows for skin sensitisation potency classification according to GHS classes. 👉 Replacement of commercial in silico prediction tools with open-source software like Skin Doctor CP and OPERA, enhancing accessibility and transparency. 👉 Use of Bayesian networks to model probabilistic knowledge, integrating diverse data sources to form evidence-based predictions for skin sensitisation potency. These new DA models showed comparable or superior accuracy to existing models, demonstrating their robustness and reliability. Furthermore, the models offered conservative and, consequently, more protective calculations of safe concentrations. These developments mark a step forward in achieving regulatory acceptance of NGRA approaches for skin sensitisation. Read more: https://lnkd.in/dqYeQXgE #SkinSensitisation #NAMs #DefinedApproaches #BayesianNetwork #IATAs #RiskAssessment #Toxicology #NGRA #AnimalFreeTesting #REACH

What do you know about 'Cannabis related hyperemesis'? Dr Chris Humphries will be presenting on this at our forthcoming Annual Scientific Conference. Dr Humphries is an ST6 EM trainee undertaking a PhD on cell therapies for paracetamol poisoning. He has worked on phase 1 and phase 2 trials for paracetamol poisoning, is a member of the RCEM Toxicology SIG, and an editor for the EMJ. The learning objectives are: ➡️ To discuss how to identify Cannabinoid Hyperemesis Syndrome (CHS) ➡️ To identify treatment options for CHS ➡️ To examine challenges RCEM guideline authors face and new evidence since the guideline was originally published Join Dr Chris Humphries and other leaders in the field of #EmergencyMedicine at #RCEMasc, 8-10 October 2024. 📢 Register here tinyurl.com/RCEMEventasc24